Government of CanadaPublic Health Agency of Canada / Agency de la santé publique du Canada
   
Skip all navigation -accesskey z Skip to sidemenu -accesskey x Skip to main menu -accesskey m  
Français Contact Us Help Search Canada Site
PHAC Home Centres Publications Guidelines A-Z Index
Child Health Adult Health Seniors HealthSurveillance Health Canada
   
    Public Health Agency of Canada (PHAC)
Canada Communicable Disease Report

 

Canada Communicable Disease Report
Volume 29 ACS-4
15 August 2003

An Advisory Committee Statement (ACS) 
National Advisory Committee on Immunization (NACI)*†

STATEMENT ON INFLUENZA VACCINATION
FOR THE 2003-2004 SEASON

Adobe Downloadable Document
20 Pages - 290 KB PDF

See also:
UPDATE: STATEMENT ON INFLUENZA VACCINATION
FOR THE 2003-04 SEASON

References

  1. British Columbia Centre for Disease Control. Epilogue: China airlines passengers' illness due to influenza, not SARS. URL: <http://www.bccdc.org/downloads/pdf/epid/reports/
    SARSUpdate_ChinaAirlines_may02-03a.pdf    >.

  2. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2003-2004 influenza season. Wkly Epidemiol Rec 2003;78:58-62.

  3. World Health Organization. Communicable disease surveillance and response. URL: <http://www.who.int/emc/diseases/flu/country.html>.

  4. Kilbourne ED, Arden NH. Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: W.B. Saunders Co., 1999;539.

  5. Shortridge KF. SARS exposed, pandemic influenza lurks. Lancet 2003;361:1649.

  6. Centers for Disease Control and Prevention. Recommendations to enhance US surveillance for influenza A (H5N1). URL: <http://www.cdc.gov/ncidod/disease/flu/hanH5N1.htm>.

  7. Abbott A. Chicken flu races through Dutch poultry farms. Nature 2003;422:247.

  8. Centers for Disease Control and Prevention. Human cases of avian influenza A (H7N7) infection, the Netherlands, 2003. URL: <http://www.cdc.gov/ncidod/diseases/flu/h7n7/facs.htm>.

  9. Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind placebo- controlled trial. Ann Intern Med 1999;131:430-33.

  10. Fine AD, Bridges CB, De Guzman AM et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis 2001;32:1784-91.

  11. Kroon FP, van Dissel JP, de Jong JC et al. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000;18:3040-49.

  12. Zanetti AR, Amendola A, Besana S et al. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 2002;20(5):B29-32.

  13. Uyeki TM, Zane SB, Bodnar UR et al. Large summertime influenza A outbreak among tourists in Alaska and the Yukon Territory. Clin Infect Dis 2003;36(9):1095-1102.

  14. Brotherton JM, Delpech VC, Gilbert GL et al. A large outbreak of influenza A and B on a cruise ship causing widespread morbidity. Epidemiol Infect 2003;130(2):263-71.

  15. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2003;52(RR-8);1-34.

  16. Potter J, Stott DJ, Roberts MA et al. Influenza vaccination of health- care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997:175;1-6.

  17. Wilde JA, McMillan JA, Serwint J et al. Effectiveness of influenza vaccine in health care professionals. A randomized trial. JAMA 1999;281:908-13.

  18. Boersma B, Rhames T, Keegan JM. Additional cost savings of an effective employee influenza program on prevention of nosocomial influenza. Am J Infect Control 1999;27:177-78.

  19. Orr P. Influenza vaccination for health care workers: a duty of care. Can J Infect Dis 2000;11(5):225-6.

  20. Herwaldt LA. Greek philosophy, medical ethics, and the influenza vaccine. Infect Control Hosp Epidemiol 1993;14:15-16.

  21. Rea E, Upshur R. Semmelweis revisited: the ethics of infection prevention among health care workers. Can Med Assoc J 2001;164(10):1447-48.

  22. Nguyen-Van-Tam J, Granfield R, Pearson J et al. Do influenza epidemics affect patterns of sickness absence among British hospital staff? Infect Control Hosp Epidemiol 1999;20:691-94.

  23. Centers for Disease Control and Prevention. General recommendations for preventing influenza infection among travelers. URL: <http://www.cdc.gov/travel/other/h5n1apr2004.htm>.

  24. 24.    Mixeu MA, Vespa GNR, Forleo-Neto E et al. Impact of influenza vaccination on civilian aircrew illness and absenteeism. Aviat Space Environ Med 2002;73:876-80.

  25. Bridges CB, Thompson WW, Meltzer MI et al. Effectiveness and cost- benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000;284:1655-63.

  26. Demicheli V, Jefferson T, Rivetti D et al. Prevention and early treatment of influenza in healthy adults. Vaccine 2000;18:957-1030.

  27. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001;161:749-59.

  28. Grotto I, Mandel Y, Green MS et al. Influenza vaccine efficacy in young, healthy adults. Clin Infect Dis 1998;26:913-17.

  29. Saxen H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J 1999;18:779-83.

  30. White T, Lavoie S, Nettleman MD. Potential cost saving attributable to influenza vaccination of school-aged children. Pediatrics 1999;103:e73.

  31. Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics 2000;106:973-76.

  32. Dayan GH, Nguyen VH, Debbag R et al. Cost-effectiveness of influenza vaccination in high-risk children in Argentina. Vaccine 2001;19:4202-13.

  33. Lee PY, Matchar DB, Clements DA et al. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 2002;137:225-31.

  34. Jefferson T, Demicheli V. Economic analysis of influenza vaccination and treatment [Letter]. Ann Intern Med 2003;138:607.

  35. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003;21(16):1769-75.

  36. Demicheli V. Mass influenza vaccination in Ontario: Is it worthwhile? Can Med Assoc J 2001;164(1):38-9.

  37. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults (Cochrane Review). In: The Cochrane Library, Oxford; issue 2, 2002.

  38. Ahmed F, Singleton JA, Franks AL. Influenza vaccination for healthy young adults. N Engl J Med 2001;345(21):1543-7.

  39. Deinhard AS, Ogburn P. A/NJ/8/76 influenza vaccination program: effects on maternal health and pregnancy outcome. Am J Obstet Gynecol 1981;140:240-45.

  40. Freeman DW, Barno A. Deaths from Asian influenza associated with pregnancy. Am J Obstet Gynecol 1959;78:1172-75.

  41. Collins SD. Age and sex incidence of influenza and pneumonia morbidity and mortality in the epidemic of 1928-1929 with comparative data for the epidemic of 1918-1919. Public Health Rep 1931;46:1909.

  42. Eickhoff TC, Sherman H, Serfling RE. Observations on excess mortality associated with epidemic influenza. JAMA 1961;176:776.

  43. Mullooly JP, Barker WH, Nolan TF. Risk of acute respiratory disease among pregnant women during influenza A epidemics. Public Health Rep 1986;101:205-11.

  44. Neuzil KM, Reed GW, Mitchel EF et al. Impact of influenza on acute cardiac pulmonary hospitalizations in pregnant women. Am J Epidemiol 1998;148:1094-1102.

  45. Bedard P-M, Gascon G. Fatal outcome of systemic vasculitis following influenza vaccination. Can J Allergy Clin Immun 1999;4:405-06.

  46. Tavadia S, Drummond A, Evans CD et al. Leucocytoclastic vasculitis and influenza vaccination. Clin Exp Dermatol 2003;28(2):154-56.

  47. Robertson WC. Carbamazepine toxicity after influenza vaccination. Pediatr Neurol 2002;26(1):61-3.

  48. Lasky T, Terracciano GJ, Magder L et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-802.

  49. McLean M, Duclos P, Jacob P et al. Incidence of Guillain-Barré syndrome in Ontario and Quebec, 1983-1989, using hospital service databases. Epidemiology 1994;5:443-48.

  50. National Advisory Committee on Immunization. Supplementary statement for the 2001-2002 season: influenza vaccination of persons who experienced oculo-respiratory syndrome following previous influenza vaccination. CCDR 2001;27(ACS-7):1-7.

  51. Spila-Alegiani S, Salmaso S, Rota MC et al. Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study. Vaccine 1999;17:1898-904.

  52. National Advisory Committee on Immunization. Supplementary Statement for the 2002-2003 influenza season: update on oculo-respiratory syndrome in association with influenza vaccination. CCDR 2002;28(ACS-6):1-8.

  53. Skowronski DM, De Serres G, Hébert J et al. Skin testing to evaluate oculo-respiratory syndrome (ORS) associated with influenza vaccination during the 2000-2001 season. Vaccine 2002;20:2713-19.

  54. Scheifele DW, Duval B, Russel ML et al. Ocular and respiratory symptoms attributable to inactivated split influenza vaccine: evidence from a controlled trial involving adults. Clin Infect Dis 2003;36:850-857.

  55. De Serres G, Grenier JL, Toth E et al. The clinical spectrum of the oculo-respiratory syndrome after influenza vaccination. Vaccine 2003;21:2354-61.

  56. Skowronski D, Strauss B, Kendall P et al. Low risk of recurrence of oculorespiratory syndrome following influenza revaccination. Can Med Assoc J 2002;167(8):853-58.

  57. De Serres G, Skowronski DM, Guay M et al. Risk of recurrence of oculo-respiratory syndrome (ORS) associated with two different influenza vaccines for 2002-2003. The Sixth Annual Conference on Vaccine Research, Arlington, VA, 5-7 May 2003, Abstract S33.

  58. De Serres G, Boulianne N, Duval B et al. Oculo-respiratory syndrome following influenza vaccination: evidence for occurrence with more than one influenza vaccine. Vaccine 2003;21:2346-53.

  59. Skowronski DM, De Serres G, Scheifele D et al. Randomized double- blind placebo controlled trial to assess the rate of recurrence of oculo- respiratory syndrome in persons previously affected following influenza vaccination. Clin Infect Dis 2003;36 (in press).

  60. National Advisory Committee on Immunization. Influenza vaccine. In: Canadian Immunization Guide. 5th ed. Ottawa, Ont.: Health Canada, 1998;103-10:140-43. Cat. No. H49-8/1998E.

  61. Duclos P, Arruda H, Dessau JC et al. Immunization survey of non-institutionalized adults - Quebec (as of May 30, 1996). CCDR 1996;22:177-82.

  62. DeWals P, Carbonneau M, Payette H, Niyonsenga T. Influenza and pneumococcal vaccination in long term care facilities in two regions of Quebec. Can J Infect Dis 1996;7:296-300.

  63. Stevenson CG, McArthur MA, Naus M et al. Prevention of influenza and pneumococcal pneumonia in Canadian long-term care facilities: How are we doing? Can Med Assoc J 2001;164(10):1413-19.

  64. Russell ML. Influenza vaccination in Alberta long-term care facilities. Can Med Assoc J 2001;164(10):1423-27.

  65. Nichol KL, Hauge M. Influenza vaccination of healthcare workers. Infect Control Hosp Epidemiol 1997;18(3):189-94.

  66. Evans MR, Watson PA. Why do older people not get immunized against influenza? A community survey. Vaccine 2003;21(19-20):2421-27.

  67. Centers for Disease Control. Influenza vaccine information for health care personnel. URL: <http://www.cdc.gov/ncidod/hip/flu_vac.htm>.

  68. Hammond GW, Cheang M. Absenteeism among hospital staff during an influenza epidemic: implications for immunoprophylaxis. Can Med Assoc J 1984;131:449-52.

  69. Yassi A, Kettner J, Hammond G et al. Effectiveness and cost-benefit of an annual influenza vaccination program for health care workers. Can J Infect Dis 1991;2:101-08.

  70. Stilianakis NI, Perelson AS, Hayden FG. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis 1998;1977:863-72.

  71. Drinka PJ, Gravenstein S, Schilling M et al. Duration of antiviral prophylaxis during nursing home outbreaks of influenza A. Arch Intern Med 1998;158:2155-59.

  72. Aoki F. Amantadine and rimantadine. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of Influenza. Oxford: Blackwell Science 1998;457-76.

  73. Buxton JA, Skowronski DM, Ng H et al. Previous creatinine levels safely predict amantadine dose for influenza A outbreak control. Can J Infect Dis 2001;12(5):185-8.

  74. McGeer A, Sitar D, Tamblyn S et al. Use of antiviral prophylaxis in influenza outbreaks in long term care facilities. Can J Infect Dis 2000;11(4):187-92.

  75. Horadam VW, Sharp JG, Smilack JD et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med 1981;94:454-58.

 

[Previous] [Canada Communicable Disease Report]
Last Updated: 2004-08-30 Top
Important Notices